DexCom (NASDAQ:DXCM – Get Rating) had its price target cut by research analysts at SVB Leerink from $565.00 to $500.00 in a report issued on Friday, The Fly reports. SVB Leerink’s target price would indicate a potential upside of 18.19% from the stock’s current price.
Other analysts have also issued research reports about the company. Wells Fargo & Company raised DexCom from an “equal weight” rating to an “overweight” rating and set a $575.00 price objective for the company in a research note on Wednesday, January 19th. Bank of America initiated coverage on DexCom in a research note on Wednesday, March 2nd. They issued a “buy” rating for the company. Robert W. Baird dropped their price target on DexCom from $625.00 to $560.00 in a research note on Friday, February 11th. Zacks Investment Research lowered DexCom from a “hold” rating to a “sell” rating and set a $452.00 price target for the company. in a research note on Tuesday, February 1st. Finally, Piper Sandler dropped their price target on DexCom from $725.00 to $480.00 in a research note on Friday. One analyst has rated the stock with a sell rating, two have given a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $544.50.
Shares of NASDAQ:DXCM traded up $9.80 during trading on Friday, reaching $423.03. 14,274 shares of the company traded hands, compared to its average volume of 827,001. The firm has a market capitalization of $41.51 billion, a price-to-earnings ratio of 273.93, a P/E/G ratio of 7.95 and a beta of 0.94. DexCom has a 52-week low of $318.45 and a 52-week high of $659.45. The company has a current ratio of 5.11, a quick ratio of 4.62 and a debt-to-equity ratio of 0.76. The business’s fifty day moving average is $455.02 and its 200-day moving average is $501.82.
DexCom (NASDAQ:DXCM – Get Rating) last released its quarterly earnings data on Thursday, April 28th. The medical device company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.52 by ($0.20). The company had revenue of $628.80 million for the quarter, compared to analysts’ expectations of $623.97 million. DexCom had a net margin of 6.32% and a return on equity of 12.87%. The business’s revenue for the quarter was up 24.5% compared to the same quarter last year. During the same period last year, the company posted $0.33 EPS. On average, sell-side analysts predict that DexCom will post 3.38 earnings per share for the current fiscal year.
In related news, Director Barbara Kahn sold 4,666 shares of DexCom stock in a transaction dated Thursday, February 10th. The stock was sold at an average price of $442.35, for a total value of $2,064,005.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Steven Robert Pacelli sold 250 shares of DexCom stock in a transaction dated Wednesday, February 23rd. The stock was sold at an average price of $394.33, for a total value of $98,582.50. The disclosure for this sale can be found here. Insiders sold a total of 10,898 shares of company stock valued at $4,835,482 over the last quarter. 0.52% of the stock is owned by corporate insiders.
A number of large investors have recently made changes to their positions in DXCM. Capital Research Global Investors boosted its position in DexCom by 55.2% in the fourth quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock worth $1,275,020,000 after purchasing an additional 844,916 shares during the last quarter. Norges Bank purchased a new position in shares of DexCom during the 4th quarter valued at about $410,670,000. Allspring Global Investments Holdings LLC purchased a new position in shares of DexCom during the 4th quarter valued at about $263,141,000. Lord Abbett & CO. LLC lifted its position in shares of DexCom by 765.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 445,677 shares of the medical device company’s stock valued at $243,723,000 after buying an additional 394,204 shares in the last quarter. Finally, EP Wealth Advisors LLC lifted its position in shares of DexCom by 49,142.7% during the 3rd quarter. EP Wealth Advisors LLC now owns 355,040 shares of the medical device company’s stock valued at $379,000 after buying an additional 354,319 shares in the last quarter. 95.14% of the stock is currently owned by institutional investors and hedge funds.
DexCom Company Profile (Get Rating)
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
- Get a free copy of the StockNews.com research report on DexCom (DXCM)
- Apple’s Numbers Complete Trifecta
- Rogers Communication Stock Should Be Launching Higher
- Iridium Communications Stock is Ready to Return to Orbit
- O’Reilly Automotive Hits A Pothole
- There’s An Institutional Floor In Keurig Dr. Pepper
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.